Lasilactone Dosage in Children
For pediatric patients requiring combination diuretic therapy, dose the individual components separately rather than using fixed-combination Lasilactone, starting with furosemide 1-2 mg/kg/day and spironolactone 1-2 mg/kg/day, with careful monitoring of electrolytes.
Individual Component Dosing
Furosemide Dosing
The FDA-approved pediatric dosing for furosemide is 2 mg/kg as a single dose initially 1. If diuretic response is inadequate, increase by 1-2 mg/kg no sooner than 6-8 hours after the previous dose. Maximum recommended dose is 6 mg/kg body weight 1.
For maintenance therapy, adjust to the minimum effective level 1. Clinical evidence supports:
- Standard dosing: 1-2 mg/kg per dose for fluid overload 2
- In neonates and infants, intermittent dosing of 1 mg/kg every 24 hours in premature infants and every 12 hours in full-term infants 3
- Continuous infusion (when tighter control needed): 0.1-0.2 mg/kg/hour, increasing to 0.4 mg/kg/hour if diuresis <1 mL/kg/hour 3
Critical caveat: Cumulative furosemide doses >10 mg/kg significantly increase nephrocalcinosis risk (48-fold increased risk) in low birth weight infants 34. Recent evidence suggests keeping total daily doses ≤2 mg/kg/day for up to 28 days mitigates this risk 4.
Spironolactone Dosing
While FDA labeling lacks specific pediatric dosing, clinical research demonstrates:
- Initial dose: 1.8 ± 0.7 mg/kg/day based on prospective observational data in 100 pediatric patients 5
- Patients with chronic lung disease received higher doses (2 ± 0.8 mg/kg/day) versus heart disease (1.7 ± 0.5 mg/kg/day) 5
- Recent pharmacokinetic data supports 1 mg/kg/dose in infants up to 2 years 6
Why Not Fixed-Combination Lasilactone?
The fixed-combination product (furosemide 20 mg + spironolactone 50 mg per capsule) 7 is not appropriate for pediatric use because:
- Dosing inflexibility: Cannot independently adjust components based on clinical response
- Weight-based dosing impossible: A 10 kg child would receive either massive overdose or inadequate therapy
- No pediatric formulation data: Studies only exist in adult hypertension 7
Electrolyte Monitoring Algorithm
Potassium monitoring is essential - the combination produces biphasic effects:
- Initial phase (first weeks): Hyperkalemia more common, especially with chronic lung disease (mean K+ 4.7 mEq/L) 5
- Long-term use: Hypokalemia becomes more frequent despite spironolactone 5
- 26% of patients required potassium supplementation in the largest pediatric series 5
Monitor potassium at:
- Baseline
- 3-7 days after initiation
- Weekly for first month
- Then monthly during chronic therapy
- After any dose adjustment
Practical Considerations
Formulation challenges: Spironolactone suspensions show significant dosing variability due to poor water solubility and sedimentation - only 28% of NICU samples and 0% of PICU samples met target dose in one study, even after educational interventions 8. This necessitates:
- Vigorous shaking before each dose
- Use of calibrated syringes
- Consideration of commercially available suspensions when possible
Drug interactions: Furosemide does not significantly increase patent ductus arteriosus closure failure when co-administered with indomethacin or ibuprofen 3, but combined use with indomethacin increases acute renal failure risk 3.